Kim Alexander R, McNeary-Garvin Antoinette, Thornton Jennifer A, Covey Carlton J
Uniformed Services University, Bethesda, MD, USA.
Family Medicine Residency Clinic (FMRC), David Grant Medical Center, Travis Air Force Base, CA, USA.
Clin Med Insights Arthritis Musculoskelet Disord. 2025 Apr 11;18:11795441251330313. doi: 10.1177/11795441251330313. eCollection 2025.
The objective was to determine whether oral non-steroidal anti-inflammatory drugs (NSAIDs) affect the efficacy of dextrose prolotherapy (DPT) in patients with knee osteoarthritis, and if the combination of these treatments is safe and well-tolerated.
Five patients with symptomatic knee osteoarthritis were included in this prospective case series. Participants underwent a series of three DPT injections at four-week intervals in their symptomatic knee(s) and were immediately prescribed a seven-day course of Ibuprofen after each injection. The main outcome measures included changes in the Knee Injury in Osteoarthritis (KOOS) questionnaire subscales (pain, symptoms, quality of life, sports and recreation function, and activities of daily living) and the Numeric Pain Rating Scale (NPRS).
There was a statistically significant improvement in the KOOS subscales of pain ( < 0.0001), Symptoms ( = 0.01), and Quality of Life ( = 0.001) after 12 weeks. The KOOS subscales for Sports and Recreation function ( = 0.06) and Activities of Daily Living ( = 0.10) showed numerical improvement over time that fell short of statistical significance. There was a statistically significant improvement in the NPRS scores compared with baseline NPRS scores after 12 weeks ( < 0.0001). In addition, NPRS scores were significantly lower at one-week follow-up after each DPT injection ( = 0.01); ( = 0.025); ( < 0.0001). There were no reported adverse events.
Concomitant use of NSAIDS with dextrose prolotherapy injections is safe and well-tolerated with no adverse events and results in improvements in pain, symptoms, and overall quality of life associated with chronic knee OA. Controlled trials of this treatment are warranted.
确定口服非甾体抗炎药(NSAIDs)是否会影响葡萄糖增殖疗法(DPT)对膝骨关节炎患者的疗效,以及这两种治疗方法联合使用是否安全且耐受性良好。
本前瞻性病例系列纳入了5例有症状的膝骨关节炎患者。参与者在其有症状的膝关节接受了一系列每四周一次、共三次的DPT注射,每次注射后立即开具为期七天的布洛芬疗程。主要结局指标包括骨关节炎膝关节损伤(KOOS)问卷子量表(疼痛、症状、生活质量、运动和娱乐功能以及日常生活活动)和数字疼痛评分量表(NPRS)的变化。
12周后,KOOS疼痛子量表(P<0.0001)、症状子量表(P=0.01)和生活质量子量表(P=0.001)有统计学意义的改善。运动和娱乐功能子量表(P=0.06)和日常生活活动子量表(P=0.10)随时间呈数值上的改善,但未达到统计学意义。与基线NPRS评分相比,12周后NPRS评分有统计学意义的改善(P<0.0001)。此外,每次DPT注射后一周随访时NPRS评分显著更低(P=0.01);(P=0.025);(P<0.0001)。未报告不良事件。
NSAIDs与葡萄糖增殖疗法注射联合使用是安全且耐受性良好的,无不良事件,并且能改善与慢性膝骨关节炎相关的疼痛、症状和总体生活质量。有必要对这种治疗方法进行对照试验。